Showing 2281-2290 of 3039 results for "".
- Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in Chinahttps://modernod.com/news/nicoxs-denali-phase-3-trial-of-ncx-470-fully-enrolled-in-china/2482561/Nicox announced that its Denali phase 3 trial evaluating the efficacy and safety of NCX 470 in patients with open-angle glaucoma or ocular hypertension is now fully enrolled in China and screening has been closed. Completion of recruitment of patients in the
- Nidek Launches NP-T Preloaded Toric IOL Injection Systemhttps://modernod.com/news/nidek-launches-np-t-preloaded-toric-iol-injection-system/2482560/Nidek announced the international launch of its NP-T Preloaded Toric IOL Injection System. Previously available exclusively in Japan, the system is now available globally. The NP-T system is designed to combine precision engineering with user-friendly design, featuring a prelo
- Melt Pharmaceuticals Announces Positive Phase 3 Trial Results for MELT-300 Sedation Solutionhttps://modernod.com/news/melt-pharmaceuticals-announces-positive-phase-3-trial-results-for-melt-300-sedation-solution/2482552/Melt Pharmaceuticals announced positive topline results from its pivotal phase 3 trial of MELT-300. This novel, non-intravenous, non-opioid tablet is designed to provide effective sedation during cataract surgery. The phase 3 study, conducted under a Special Protocol Assessment (SPA) ag
- Ocugen Reports Positive Preliminary Data from OCU410 Trial for Geographic Atrophyhttps://modernod.com/news/ocugen-reports-positive-preliminary-data-from-ocu410-trial-for-geographic-atrophy/2482550/Ocugen announced encouraging preliminary results from the phase 1 portion of its phase 1/2 OCU410 ArMaDa clinical trial for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The trial, which includes nine patients across three dose cohorts, revealed promis
- Oklahoma Neonatologist-Researcher Earns NIH Grant to Advance Retinopathy of Prematurityhttps://modernod.com/news/oklahoma-neonatologist-researcher-earns-nih-grant-to-advance-retinopathy-of-prematurity/2482537/Faizah Bhatti, MD, was the first to discover the presence of surfactant protein A in the eye–a key protein related to blood vessel growth and previously believed to only exist in the lung. Now, the University of Oklahoma neonatologist and researcher has earned a 5-year, $2.3 million grant f
- Tarsus Appoints Elizabeth Yeu, MD, as Chief Medical Officerhttps://modernod.com/news/tarsus-appoints-elizabeth-yeu-md-as-chief-medical-officer/2482527/Tarsus Pharmaceuticals announced the appointment of Elizabeth Yeu, MD, as chief medical officer, effective November 4, 2024. A distinguished ophthalmologist with more than two decades of clinical experience and leadership, Dr. Yeu has served as Tarsus’ chief medical advisor s
- LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMDhttps://modernod.com/news/lumithera-obtains-fda-authorization-of-valeda-treatment-for-dry-amd/2482525/The FDA has granted authorization to LumiThera allowing the company to market its Valeda Light Delivery System. This approval, made under the De Novo authorization pathway, makes Valeda the first FDA-authorized device to treat vision loss in patients with dry AMD.
- Cathleen McCabe, MD, Appointed Strategic Medical Advisor at Bausch + Lombhttps://modernod.com/news/cathleen-mccabe-md-appointed-strategic-medical-advisor-at-bausch-lomb/2482507/Bausch + Lomb has appointed Cathleen McCabe, MD, as Strategic Medical Advisor. According to B+L, in this new consultancy role, Dr. McCabe will contribute her expertise to Bausch + Lomb’s product portfolio expansion and collaborate with the research and development team to drive in
- Ocular Therapeutix Announces Accelerated Timelines for SOL-1 Registrational Trial of Axpaxli in Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-accelerated-timelines-for-sol-1-registrational-trial-of-axpaxli-in-wet-amd/2482490/Ocular Therapeutix announced an acceleration of the SOL-1 phase 3 registrational clinical trial of Axpaxli for wet age-related macular degeneration (wet AMD). The company now expects to complete enrollment and randomization by the end of 2024, ahead of previous guidance to finish by the first qua
- Melt Announces Completion of Patient Dosing in Phase 3 Study of MELT-300 for Procedural Sedationhttps://modernod.com/news/melt-pharmaceuticals-announces-completion-of-patient-dosing-in-phase-3-study-of-melt-300-for-procedural-sedation/2482477/Melt Pharmaceuticals announced the completion of patient dosing in its pivotal phase 3 clinical trial. This study evaluates the safety and efficacy of MELT-300, the company's lead product candidate, for providing non-intravenous, non-opioid sedation during cataract surgery. MELT-300